BHC Invests in 20/20 GeneSystems to Bring Lung Cancer Test to China | GenomeWeb

NEW YORK (GenomeWeb) – BHC Center of Financial and Investment Business today announced it has invested in 20/20 GeneSystems to help bring the company's diagnostic test for lung cancer to China.

BHC, an Atlanta-based affiliate of Bao Hao Investment Management of Shanghai, said that the equity investment is the first of what it expects to be several in 20/20 GeneSystems. BHC did not disclose the amount of the investment.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.